UROGENITAL NEOPLASMS
Clinical trials for UROGENITAL NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new UROGENITAL NEOPLASMS trials appear
Sign up with your email to follow new studies for UROGENITAL NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a targeted drug delay prostate cancer progression?
Disease control OngoingThis phase 3 trial tests whether adding the targeted drug abemaciclib to standard hormone therapy (abiraterone plus prednisone) can delay cancer growth in men with high-risk prostate cancer that has spread to bones or organs. Participants receive either abemaciclib or a placebo a…
Matched conditions: UROGENITAL NEOPLASMS
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
New drug targets rare cancer mutation in early trial
Disease control OngoingThis early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…
Matched conditions: UROGENITAL NEOPLASMS
Phase: PHASE1 • Sponsor: Atavistik Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
NanoDoce made available for urogenital cancer patients outside trials
Disease control NO_LONGER_AVAILABLEThis program offers expanded access to NanoDoce for patients with urogenital cancers who cannot join ongoing clinical trials. The goal is to provide the treatment to those in need. No specific eligibility details are listed.
Matched conditions: UROGENITAL NEOPLASMS
Sponsor: NanOlogy, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC